• Explore /
  • Poster
  • / A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.

A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.

Abstract Poster

Authors

null

Fabian Trillsch

University Hospital LMU Munich, Munich, Germany

Fabian Trillsch , Fabienne Schochter , Tjoung-Won Park-Simon , Alexander Reuss , Tanja N. Fehm , Pauline Wimberger , Holger Bronger , Barbara Schmalfeldt , Jalid Sehouli , Frederik Marmé , Florian Heitz , Sven Mahner , Michaela Fredrich , Stefanie Barth , James Joseph Stec , Michael W. Method , Philipp Harter

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04274426

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5618)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5618

Abstract #

TPS5618

Poster Bd #

485b

Abstract Disclosures

Similar Posters

First Author: Mansoor Raza Mirza

First Author: Alexandra Leary

First Author: JUNG-YUN LEE

First Author: Alexandra Leary